focus -WSS

focus

author：entertainment 2025-09-30 00:47:15 - browse：27568

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： WuXi Biologics beefs up its lobbying operation

knowledge

focus

WSS

WuXi Biologics execs register to lobby as Congress comes for the company

Vertex non

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Why you shouldn’t ask, “What country has the best health care?”

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Oak Street deal isn't the answer to health care's woes

knowledge

focus

focus

ChatGPT in medicine: STAT answers readers' burning questions

10 reasons why health care startups fail

Peter Hotez and the public health issue of online harassment

Pancreatic cancer early detection could be helped by AI

United colonoscopy coverage change 'may cost lives,' doctors say

Pancreatic cancer early detection could be helped by AI

Trump demands the U.S. pay no more for drugs than other countries … again

Novo Nordisk testing Wegovy against alcohol

Medical leaders decry Supreme Court decision on affirmative action

Lilly’s weekly insulin works as well as daily products, new studies show

explore

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Humana’s losses in Medicare Advantage tank its stock

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Health Care Service Corp to buy Cigna Medicare Advantage plans

How generative AI ratchets up security threats for health systems

entertainment

knowledge

focus

hotspot